title: Does the addition of chemotherapy to adjuvant endocrine treatment add any benefit in ER-positive early breast cancer: can we rely on large randomized control trials in the era of personalized medicine?
authors.affiliation: Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, USA. Electronic address: sgluck@med.miami.edu.
authors.forename: S
authors.initials: S
authors.lastname: Glück
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate